New MEK inhibitor, trametinib, improves survival in advanced melanoma

Share :
Published: 4 Jun 2012
Views: 4068
Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France

At a press conference during the ASCO 2012 Annual Meeting in Chicage, June 1st - June 4th, Dr Caroline Robert presented data from a Phase III study showing that the oral investigational drug trametinib delayed tumour growth and extended survival for patients with advanced melanoma who have BRAF mutations, compared with standard chemotherapy.